ストックスクリーナーアプリを入手
0.5218
10.03%
-0.0582
アフターアワーズ：
.52
-0.0018
-0.34%
前日終値:
$0.58
開ける：
$0.5701
24時間の取引高:
21.09M
Relative Volume:
1.66
時価総額：
$120.77M
収益：
-
当期純損益:
$-179.82M
株価収益率:
-0.3923
EPS:
-1.33
ネットキャッシュフロー:
$-159.16M
1週間 パフォーマンス:
+29.80%
1か月 パフォーマンス:
-78.57%
6か月 パフォーマンス:
-82.25%
1年 パフォーマンス:
-55.78%
1日の値動き範囲:
$0.4755
$0.5701
1週間の範囲:
$0.39
$0.5982
52週間の値動き範囲:
$0.3312
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Compare GOSS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.5218 | 134.24M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2025-09-10 | アップグレード | UBS | Neutral → Buy |
| 2025-07-14 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-04-05 | 再開されました | Wedbush | Outperform |
| 2023-07-27 | ダウングレード | UBS | Buy → Neutral |
| 2023-03-07 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | 開始されました | Guggenheim | Neutral |
| 2022-12-07 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-12-07 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-12-07 | ダウングレード | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | 開始されました | Goldman | Buy |
| 2022-09-21 | 開始されました | JP Morgan | Neutral |
| 2022-09-19 | 開始されました | Wedbush | Outperform |
| 2022-04-18 | 開始されました | Raymond James | Outperform |
| 2022-04-06 | 開始されました | UBS | Buy |
| 2022-01-10 | アップグレード | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-09-21 | 再開されました | Piper Sandler | Overweight |
| 2020-06-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-22 | 開始されました | Piper Sandler | Overweight |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-30 | 開始されました | Berenberg | Buy |
| 2019-03-05 | 開始されました | Barclays | Overweight |
| 2019-03-05 | 開始されました | BofA/Merrill | Buy |
| 2019-03-05 | 開始されました | Evercore ISI | Outperform |
| 2019-03-05 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Gossamer Bio Inc (GOSS) 最新ニュース
Oppenheimer Lowers Gossamer Bio (NASDAQ:GOSS) Price Target to $3.00 - MarketBeat
Oppenheimer Maintains Outperform Rating, Lowers PT on Gossamer B - GuruFocus
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Earnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to Decline - Finviz
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails - GlobeNewswire
GOSS: Announces Topline Results for Phase 3 PROSERA Trial — LEVI & KORSINSKY, LLP - The Malaysian Reserve
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Gossamer Bio, Inc. (NASDAQ:GOSS) Given Average Rating of "Hold" by Brokerages - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Investors to Connect - ACCESS Newswire
GOSS Stock Quote Price and Forecast - CNN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc.GOSS - ChartMill
GOSS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Stockholders to Connect - ACCESS Newswire
683 Capital reports 5.23% stake in Gossamer Bio | GOSS SEC FilingForm SCHEDULE 13G - Stock Titan
GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
2026-03-01 | Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:GOSS | Press Release - Stockhouse
Should You Buy Gossamer Bio Inc (GOSS) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2026-02-27 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Stockholders to Learn More About the Investigation | NDAQ:GOSS | Press Release - Stockhouse
Gossamer Bio (GOSS) Loses 85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Finviz
Here's Why Gossamer Bio (GOSS) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Gossamer Bio, Inc. (GOSS) Stock Analysis: Exploring the 1,395.85% Potential Upside for Investors - DirectorsTalk Interviews
Gossamer Bio (NASDAQ:GOSS) Downgraded to Hold Rating by The Goldman Sachs Group - MarketBeat
Guggenheim Sticks to Their Hold Rating for Gossamer Bio (GOSS) - The Globe and Mail
Gossamer Bio (GOSS) Reports Topline Phase 3 Results for Seralutinib in Pulmonary Arterial Hypertension - Finviz
Quarterly Trades: Should I set a stop loss on Gossamer Bio IncJuly 2025 Trends & Technical Pattern Based Signals - baoquankhu1.vn
Gossamer, Grail down by more than half after late-stage misses - biocentury.com
Barclays downgrades Gossamer Bio (GOSS) - MSN
Gossamer Bio (GOSS) Downgraded by Wedbush with Significant PT Re - GuruFocus
Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial HypertensionSlideshow (NASDAQ:GOSS) 2026-02-24 - Seeking Alpha
Gossamer Bio stock downgraded by Wedbush on trial results - Investing.com South Africa
Gossamer Bio (GOSS) Downgraded by Wedbush with Significant PT Reduction | GOSS Stock News - GuruFocus
These Analysts Slash Their Forecasts On Gossamer Bio - Benzinga
GOSS: Analyst Downgrades and Price Target Slashes by Leerink Par - GuruFocus
Gossamer Bio (GOSS) Faces Downgrade Amid Study Challenges and Ma - GuruFocus
Gossamer Bio (NASDAQ:GOSS) Rating Lowered to Neutral at Wedbush - MarketBeat
This Novo Nordisk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Barclays cuts Gossamer Bio stock rating on trial results By Investing.com - Investing.com Australia
Leerink Downgrades Gossamer Bio to Market Perform From Outperform, Adjusts Price Target to $1 From $6 - marketscreener.com
Barclays Downgrades Gossamer Bio to Underweight From Overweight, Adjusts Price Target to $0.30 From $9 - marketscreener.com
Wedbush Downgrades Gossamer Bio to Neutral From Outperform, Cuts Price Target to $1 From $6 - marketscreener.com
Leerink cuts Gossamer Bio stock rating on trial miss - Investing.com Australia
Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story - TechStock²
Barclays cuts Gossamer Bio stock rating on trial results - Investing.com
Gossamer Bio’s seralutinib misses primary endpoint in PAH trial By Investing.com - Investing.com India
Leerink cuts Gossamer Bio stock rating on trial miss By Investing.com - Investing.com Canada
GOSS: Gossamer Bio's Phase 3 Study of Seralutinib Shows Promise in PAH - GuruFocus
Gossamer Bio stock plummeted 82% today — what’s behind the crash? - MSN
Gossamer Bio’s seralutinib misses primary endpoint in PAH trial - Investing.com Australia
Gossamer Bio’s Phase 3 PROSERA PAH Trial Misses Primary Endpoint Despite Numerical 6MWD Gain - MarketBeat
Gossamer Bio Inc (GOSS) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):